Systematic adjuvant therapy has improved the outcome for women with operable breast cancer.
As a result, a substantial proportion of patients with this disease are candidates for adjuvant treatment.
In providing a woman with recommendations for therapy, her risk of developing recurrent breast cancer needs to be assessed in relationship to the degree of benefit she will obtain from treatment.
With the range of presently available treatments, an individualized approach is necessary to provide the patient with options appropriate for her own situation.
For women with a high risk of recurrence despite current standard adjuvant therapies, innovative approaches with high dose chemotherapy followed by infusion of autolo-gous hematopoietic stem cells and growth factors are being evaluated.
Ongoing clinical trials will demonstrate whether or not these newer therapies result in a better outcome.
Mots-clés Pascal : Carcinome, Glande mammaire, Traitement adjuvant, Chimiothérapie, Antioestrogène, Tamoxifène, Indication, Analyse avantage coût, Homme, Femelle, Composé non stéroïde, Tumeur maligne, Glande mammaire pathologie, Economie santé
Mots-clés Pascal anglais : Carcinoma, Mammary gland, Adjuvant treatment, Chemotherapy, Antiestrogen, Tamoxifene, Indication, Cost benefit analysis, Human, Female, Non steroid compound, Malignant tumor, Mammary gland diseases, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0210466
Code Inist : 002B02R02. Création : 21/05/1997.